StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Aptevo Therapeutics Price Performance
APVO stock opened at $0.39 on Friday. Aptevo Therapeutics has a 1 year low of $0.36 and a 1 year high of $7.20. The firm has a 50-day moving average of $0.68 and a 200 day moving average of $1.36.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.11). On average, sell-side analysts expect that Aptevo Therapeutics will post -2.37 EPS for the current fiscal year.
Hedge Funds Weigh In On Aptevo Therapeutics
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.
- Five stocks we like better than Aptevo Therapeutics
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What is a Death Cross in Stocks?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- What is Forex and How Does it Work?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.